相关实验视频

Updated: Jul 3, 2025

Using X-ray Crystallography, Biophysics, and Functional Assays to Determine the Mechanisms Governing T-cell Receptor Recognition of Cancer Antigens

Using X-ray Crystallography, Biophysics, and Functional Assays to Determine the Mechanisms Governing T-cell Receptor Recognition of Cancer Antigens

Published on: February 6, 2017

异环基改性伊米达佐基诺林衍生物:选择性TLR7激动剂调节瘤微环境对抗黑色素瘤

Jiaxin Ou¹, Lu Zheng¹, Yanlin Chen¹

¹Guangdong Provincial Key Laboratory of New Drug Screening, NMPA Key Laboratory for Research and Evaluation of Drug Metabolism and Guangdong-Hong Kong-Macao Joint Laboratory for New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China.

Journal of medicinal chemistry

|February 16, 2024

概括

一种新型的小分子,SMU-L11,有效地激活类似收费受体7 (TLR7) 以刺激抗瘤免疫力. 这种免疫治疗剂增强了免疫细胞的功能,并在临床前模型中抑制了瘤的生长.

科学领域:

免疫学免疫学免疫学
药理学药理学是指药理学的学科.
在瘤学瘤学.

背景情况:

收费类受体7 (TLR7) 激动剂是有前途的癌症免疫疗法.
伊米达佐基诺林衍生物为开发强大的TLR7激动剂提供了支架.

研究的目的:

为了设计和合成基于imidazoquinoline的新型TLR7激动剂.
为了确定癌症免疫治疗中最强大的小分子TLR7激动剂.
为了评估化合物的体外和体内疗效.

主要方法:

合成伊米达佐基诺林衍生物.
使用HEK-Blue hTLR7细胞进行NF-κB通路激活测定.
在体外细胞因子诱导和巨细胞极化试验.
在B16-F10小鼠模型中的体内瘤生长抑制研究.

主要成果:

发现SMU-L11是一种强大的TLR7激动剂 (EC50=0.024±0.002μM).
SMU-L11激活了TLR7,导致MyD88的招募和NF-κB/MAPK通路的激活.
SMU-L11诱导了促炎性细胞因子和M1巨细胞极化.
在体内,SMU-L11增强了免疫细胞激活,T细胞增殖,并抑制了瘤生长.

结论:

SMU-L11是一种强大的TLR7激动剂,具有显著的免疫增强特性.
SMU-L11显示出作为一种新型癌症免疫治疗剂的潜力.
需要对SMU-L11进行进一步的临床应用研究.

更多相关视频

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

相关概念视频

The Tumor Microenvironment

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...